Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart stent study seeks to predict blockage return with advanced lipid test

NCT ID NCT07533656

Knowledge-focused Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study involves 3,600 people who have had a heart stent placed. Researchers want to see if a special cholesterol test (VAP) can help predict when the artery narrows again. Participants provide a blood sample from routine care, and no extra blood draws are needed. The goal is to better understand risk factors for stent re-blockage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with coronary artery disease/ASCVD undergoing prior PCI with repeat coronary angiography or undergoing index PCI at participating centers, with clinical data sufficient for ASCVD risk assessment and serum samples available for VAP-based lipid and lipoprotein subfraction testing.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Retrospective cross-sectional component: * Age \>=18 years * Prior successful implantation of second-generation drug-eluting stents * Repeat coronary angiography available at a participating center * Complete data available for ASCVD risk assessment * Stored serum sample available for VAP testing * Angiographic data sufficient to determine ISR status Prospective component: * Age \>=18 years * Undergoing index PCI * Planned routine follow-up coronary angiography * Complete data available for ASCVD risk assessment * Serum sample available from routine clinical blood collection * Able to provide written informed consent and any required privacy authorization Exclusion Criteria: * Severe hepatic dysfunction (ALT or AST \>3 x ULN or Child-Pugh class C) * Prior CABG with angioplasty performed in a non-native vessel * In-stent restenosis occurring within 1 month after PCI * Expected survival \<1 year (prospective component)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary restenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease In-stent restenosis

Contacts and locations

Locations

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.